Cerebrolysin®: a guide to its use in dementia
- 37 Downloads
Cerebrolysin® is a brain-derived peptide preparation with pharmacodynamic properties that are similar to those of endogenous neurotrophic factors. In patients with Alzheimer’s disease or vascular dementia, Cerebrolysin® improved global outcome measures and cognitive ability and was generally well tolerated.
What is the rationale for developing the drug?
Alzheimer’s disease (≈50–70% of cases). An age-related neurodegenerative disorder that is usually associated with a gradual decline in cognitive function
Vascular dementia (≈30% of cases). Can develop after successive strokes, small vessel disease or because of other mechanisms. Often has a rapid onset.
In general, most treatments for dementia (including the widely used cholinesterase inhibitors) do not reverse or halt disease...
- 2.Cerebrolysin® solution for injection: summary of product characteristics. Unterach, Austria: Ever Neuro Pharma GmbH, 2009 DecGoogle Scholar
- 7.Alvarez XA, Cacabelos R, Sampedro C, et al. Efficacy and safety of Cerebrolysin in moderate to moderately severe Alzheimer’s disease: results of a randomized, double-blind, controlled trial investigating three dosages of Cerebrolysin. Eur J Neurol. Epub 2010 May 25Google Scholar
- 8.Ruether E, Alvarez XA, Rainer M, et al. Sustained improvement of cognition and global function in patients with moderately severe Alzheimer’s disease: a double-blind, placebo-controlled study with the neurotrophic agent Cerebrolysin®. J Neural Transm 2002; 62 Suppl.: 265–75Google Scholar
- 9.Alvarez A, Cacabelos R, Aleixandre M, et al. Synergistic treatment effects with Cerebrolysin and donepezil: results from a randomized, double-blind, multicenter trial to compare safety and efficacy of Cerebrolysin, donepezil and a combination of both in patients with probable Alzheimer’s disease [abstract]. International Conference on Alzheimer’s Disease; 2009 Jul 11–16; ViennaGoogle Scholar
- 10.Alvarez XA, Cacabelos R. Integrated clinical study report (protocol EBE031010). A randomized, double-blind, clinical trial to compare the safety and efficacy of a Cerebrolysin and Aricept (donepezil) and a combination therapy in patients with probable Alzheimer’s disease. Unterach, Austria: EBEWE Neuro Pharma GmbH, 2008 Nov 27. (Data on file)Google Scholar
- 11.Gavrilova SI, Kolykhalov IV, Korovaitseva GI, et al. ApoE genotype and efficacy of neurotrophic and cholinergic therapy in Alzheimer’s disease [in Russian]. Zh Nevrol Psikhiatr Im SS Korsakova 2005; 105(4): 27–34Google Scholar
- 12.Guekht A, Moessler H, Doppler E, et al. Cerebrolysin in vascular dementia: improvement of clinical outcome in a randomized, double-blind, placebo-controlled multicenter trial [abstract plus poster]. 9th International Conference for Alzheimer’s and Parkinson’s Disease; 2009 Mar 11–15; PragueGoogle Scholar
- 13.Gusev EI. Integrated clinical study report (protocol EBE-RU-051201). A randomized, double-blind, placebo-controlled clinical trial to evaluate the safety and efficacy of 20 ml Cerebrolysin in patients with vascular dementia. Unterach, Austria: EBEWE Neuro Pharma GmbH, 2008 Aug 18. (Data on file)Google Scholar
- 14.Vereschagin NV, Nekrasova EM, Lebedova NV, et al. Mild forms of multi-infarct dementia: effectiveness of cerebrolysin [in Russian]. Sov Med 1991; (11): 6–8Google Scholar
- 15.Xiao S, Yan H, Yao P. The efficacy of cerebrolysin in patients with vascular dementia: results of a Chinese multicentre, randomised, double-blind, placebo-controlled trial. The Cerebrolysin Study Group. Hong Kong J Psychiatry 1999; 9(2): 13–9Google Scholar
- 16.Muresanu DF. The influence of Cerebrolysin on cognitive performances in patients suffering from vascular dementia. Unterach, Austria: EBEWE Pharmaceuticals Ltd, 1999Google Scholar